Novartis | NOVN - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 6.57B 2.82B 2026-06
Alcon AG USD 1.58B 80M 2026-03
Almirall EUR 337.77M 14.83M 2025-12
Amgen USD 13.99B 1.95B 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
Autolus Therapeutics Ltd USD 171.41M 40.49M 2026-06
Bayer EUR 4.29B 1.44B 2026-06
Biogen USD 1.28B 2.1B 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
Eli Lilly USD 8.95B 3.67B 2026-06
Fresenius EUR 2.06B 752M 2026-03
Fresenius Medical Care EUR 1.06B 177.89M 2026-06
Genmab DKK 1.5B 18M 2026-06
Gilead Sciences USD 7.63B 64M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
GRIFOLS EUR 513M 189M 2026-06
Hikma Pharmaceutical USD 217M 19M 2025-12
J&J USD 20.42B 1.27B 2026-06
Lakefront Biotherapeutics EUR 135.95M 69.15M 2026-06
Lonza CHF 719M 188M 2025-12
Merck EUR 2.74B 415M 2026-03
Merck USD 6.85B 1.52B 2026-06
Novartis USD 7.62B 739M 2026-06
Novartis USD 6.88B 2.68B 2026-03
Novo Nordisk A/S DKK 18.44B 5.78B 2025-06
Orion EUR 199.3M 38.4M 2026-03
Pfizer USD 976M 727M 2026-06
Philips EUR 1.79B 803M 2026-06
Recordati EUR 391.38M 10.92M 2026-06
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 6.35B 806M 2026-06
UCB EUR 1.57B 1.14B 2024-12